Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit

Rhea-AI Summary

Adverum Biotechnologies (Nasdaq: ADVM) announced that COO Peter Soparkar will present at the Jefferies Cell and Genetic Medicine Summit on September 29, 2022, at 9:30 a.m. ET. The event will focus on gene therapy innovations targeting prevalent ocular diseases, aiming to transform treatment standards and preserve vision. An on-demand webcast of the presentation will be accessible on Adverum's website for 90 days following the event. The company is developing a one-time gene therapy injection, Ixo-vec, for treating wet age-related macular degeneration.

REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Peter Soparkar, chief operating officer of Adverum Biotechnologies, will present at the Jefferies Cell and Genetic Medicine Summit on September 29, 2022, at 9:30 a.m. ET.

The on-demand webcast corporate presentation may be accessed under Events and Presentations in the Investors section of Adverum’s website. A replay of the webcast will be available on the website for 90 days following the presentation.

About Adverum Biotechnologies

Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.

Corporate & Investor Inquiries

Anand Reddi
Vice President, Head of Corporate Strategy, External Affairs and Engagement
Adverum Biotechnologies, Inc.
T: 650-649-1358
E: areddi@adverum.com

Media

Megan Talon
Associate Director, Corporate Communications
Adverum Biotechnologies, Inc.
T: 650-649-1006
E: mtalon@adverum.com

FAQ

When will Peter Soparkar present at the Jefferies Cell and Genetic Medicine Summit?

Peter Soparkar will present on September 29, 2022, at 9:30 a.m. ET.

Where can I access the webcast of Adverum's presentation?

The on-demand webcast can be accessed in the Events and Presentations section of Adverum's website.

What is Ixo-vec and its significance for ADVM?

Ixo-vec is a novel gene therapy candidate being developed by Adverum for a one-time, intravitreal injection to treat wet age-related macular degeneration.

How long will the presentation replay be available?

A replay of the webcast will be available for 90 days after the presentation.

What disease does Adverum Biotechnologies aim to treat?

Adverum focuses on developing gene therapies for highly prevalent ocular diseases.